Genome sequencing identifies a basis for everolimus sensitivity

Science

Volumn 338, Issue 6104, 2012, Pages 221-

  Iyer, Gopa ^a   Hanrahan, Aphrothiti J ^a   Milowsky, Matthew I ^a   Al Ahmadie, Hikmat ^a   Scott, Sasinya N ^a   Janakiraman, Manickam ^a   Pirun, Mono ^a   Sander, Chris ^a   Socci, Nicholas D ^a   Ostrovnaya, Irina ^a   Viale, Agnes ^a   Heguy, Adriana ^a   Peng, Luke ^a   Chan, Timothy A ^a   Bochner, Bernard ^a   Bajorin, Dean F ^a   Berger, Michael F ^a   Taylor, Barry S ^a   Solit, David B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EVEROLIMUS; NEUROFIBROMATOSIS TYPE 2; TUBEROUS SCLEROSIS COMPLEX 1; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

GENOME; SENSITIVITY ANALYSIS;

BASE PAIRING; BLADDER CANCER; CANCER SURVIVAL; COPY NUMBER VARIATION; DNA SEQUENCE; DRUG TARGETING; GENE EXPRESSION; GENE SEQUENCE; INDEL MUTATION; LOSS OF FUNCTION MUTATION; METASTASIS; MISSENSE MUTATION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SHORT SURVEY; STOP CODON; TREATMENT RESPONSE; TUMOR GENE;

EID: 84867333656     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1226344     Document Type: Short Survey

References (4)

1. Materials and methods are available as supplementary materials on Science Online.
2. M. A. López-Lago, T. Okada, M. M. Murillo, N. Socci, F. G. Giancotti, Mol. Cell. Biol. 29, 4235 (2009).
3. F. M. Platt et al., Clin. Cancer Res. 15, 6008 (2009).
4. D. A. Krueger et al., N. Engl. J. Med. 363, 1801 (2010).